Lichen China GAAP EPS of -$0.71, revenue of $10.26M (NASDAQ:LICN)
Lichen China (LICN) reported a GAAP EPS of -$0.71 and revenue of $10.26M for the first half of 2026, down 28.1% year-over-year. The company's cash and cash equivalents decreased to $19.60M as of June 30, 2026, from $26.91M at the end of 2025.
How this was made
The 30-second read
Why it matters
Earnings miss and cash decline may trigger short‑term sell pressure; investors will watch for any partnership news.
Market read
Micro‑cap earnings miss with modest financial figures; relevance primarily to niche biotech traders.
What to watch
Cash runway may support short‑term operations; no guidance provided.
Background
Lichen China is a small biotech listed on NASDAQ, reporting its first‑half 2026 results.
Ticker impact
1H GAAP EPS of -$0.71, revenue down 28.1% YoY to $10.26M, cash fell to $19.6M.
likely pressure as the market prices in the earnings miss and cash burn
Micro‑cap earnings miss typically triggers sell‑off; limited upside without guidance.
Market effects
Highlights weakness in niche biotech/clinical‑trial services sector.
Limited to U.S. micro‑cap investors; no broader regional effect.
Minimal global impact due to small market cap.
Counterpoint
If the company secures a new partnership, the stock could rebound despite the miss.
Key entities
- CompanyLichen China
NASDAQ‑listed biotech reporting 1H 2026 results.
